Metabolic, renal, and inflammatory crosstalk in atherosclerotic cardiovascular disease: Evolving landscape and future directions.
作者信息
Avgousti Harris, Feinstein Matthew J
机构信息
Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, United States.
Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, United States.
出版信息
Atherosclerosis. 2025 Jun;405:119199. doi: 10.1016/j.atherosclerosis.2025.119199. Epub 2025 Apr 15.
Abstract
摘要
相似文献
1
Metabolic, renal, and inflammatory crosstalk in atherosclerotic cardiovascular disease: Evolving landscape and future directions.动脉粥样硬化性心血管疾病中的代谢、肾脏及炎症交互作用：不断演变的格局与未来方向
Atherosclerosis. 2025 Jun;405:119199. doi: 10.1016/j.atherosclerosis.2025.119199. Epub 2025 Apr 15.
2
Atherosclerotic renal artery stenosis: current status and future directions.动脉粥样硬化性肾动脉狭窄：现状与未来方向
Curr Opin Nephrol Hypertens. 2004 Nov;13(6):613-21. doi: 10.1097/00041552-200411000-00006.
3
The Interplay of Atherothrombotic Factors and the Evolving Landscape of Atherosclerotic Cardiovascular Disease: Comprehensive Insights from Recent Studies.动脉粥样硬化血栓形成因素的相互作用与动脉粥样硬化性心血管疾病的演变态势：近期研究的全面见解
Anatol J Cardiol. 2024 Jul 16;28(8):375-80. doi: 10.14744/AnatolJCardiol.2024.4632.
4
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management.残余心血管风险管理的认知与方法的演变
Front Cardiovasc Med. 2020 May 13;7:88. doi: 10.3389/fcvm.2020.00088. eCollection 2020.
5
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.SGLT2 抑制剂用于 2 型糖尿病的心血管和肾脏结局的一级和二级预防：心血管结局试验的系统评价和荟萃分析。
Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10.
6
The Atherosclerotic Plaque Microenvironment as a Therapeutic Target.作为治疗靶点的动脉粥样硬化斑块微环境
Curr Atheroscler Rep. 2025 Apr 2;27(1):47. doi: 10.1007/s11883-025-01294-y.
7
Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.二甲双胍对腹型肥胖、代谢综合征和2型糖尿病患者心血管疾病风险管理的潜在贡献。
Diabetes Metab. 2003 Sep;29(4 Pt 2):6S53-61. doi: 10.1016/s1262-3636(03)72788-8.
8
Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.对称二甲基精氨酸（SDMA）在预测非透析慢性肾脏病的肾脏和心血管结局方面优于不对称二甲基精氨酸（ADMA）和其他甲基精氨酸。
Clin Res Cardiol. 2018 Mar;107(3):201-213. doi: 10.1007/s00392-017-1172-4. Epub 2017 Nov 3.
9
Deciphering the emerging landscape of HOX genes in cardiovascular biology, atherosclerosis and beyond (Review).解析 HOX 基因在心血管生物学、动脉粥样硬化及其他领域中的新兴作用（综述）。
Int J Mol Med. 2024 Feb;53(2). doi: 10.3892/ijmm.2023.5341. Epub 2023 Dec 22.
10
Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association.亚裔美国人成年人群中的糖尿病和动脉粥样硬化性心血管疾病的流行病学：意义、管理和未来方向：美国心脏协会的科学声明。
Circulation. 2023 Jul 4;148(1):74-94. doi: 10.1161/CIR.0000000000001145. Epub 2023 May 8.
本文引用的文献
1
Global burden and national health inequity of ischemic heart disease attributed to kidney dysfunction from 1990 to 2021: Findings from the global burden of disease study 2021.1990年至2021年因肾功能不全所致缺血性心脏病的全球负担及国家健康不平等：全球疾病负担研究2021的结果
Atherosclerosis. 2025 Jun;405:119140. doi: 10.1016/j.atherosclerosis.2025.119140. Epub 2025 Feb 26.
2
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2025.11. 慢性肾脏病与风险管理：2025年糖尿病护理标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S239-S251. doi: 10.2337/dc25-S011.
3
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.胰高血糖素样肽-1受体激动剂对肾脏和心血管疾病结局的影响：一项随机对照试验的荟萃分析。
Lancet Diabetes Endocrinol. 2025 Jan;13(1):15-28. doi: 10.1016/S2213-8587(24)00271-7. Epub 2024 Nov 25.
4
Temporal trend and attributable risk factors of cardiovascular disease burden for adults 55 years and older in 204 countries/territories from 1990 to 2021: an analysis for the Global Burden of Disease Study 2021.1990年至2021年204个国家/地区55岁及以上成年人心血管疾病负担的时间趋势和可归因风险因素：全球疾病负担研究2021分析
Eur J Prev Cardiol. 2025 May 12;32(7):539-552. doi: 10.1093/eurjpc/zwae384.
5
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association.心血管-肾脏-代谢（CKM）综合征的科学证据和临床管理概要：美国心脏协会的科学声明
Circulation. 2023 Nov 14;148(20):1636-1664. doi: 10.1161/CIR.0000000000001186. Epub 2023 Oct 9.
6
Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection.胰高血糖素样肽-1受体激动剂在糖尿病肾病中的应用：肾脏与心脏保护作用综述
Am J Prev Cardiol. 2023 May 24;14:100502. doi: 10.1016/j.ajpc.2023.100502. eCollection 2023 Jun.
7
Cause-Specific Mortality in Patients With Advanced Chronic Kidney Disease in the ISCHEMIA-CKD Trial.缺血性肾病-慢性肾脏病（ISCHEMIA-CKD）试验中晚期慢性肾脏病患者的病因特异性死亡率。
JACC Cardiovasc Interv. 2023 Jan 23;16(2):209-218. doi: 10.1016/j.jcin.2022.10.062.
8
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.SGLT2 抑制剂的心脏-肾脏保护机制概述。
Int J Mol Sci. 2022 Mar 26;23(7):3651. doi: 10.3390/ijms23073651.
9
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.SGLT2 抑制剂与 2 型糖尿病患者心血管和肾脏结局的关联：一项荟萃分析。
JAMA Cardiol. 2021 Feb 1;6(2):148-158. doi: 10.1001/jamacardio.2020.4511.
10
Innate immunity in diabetic kidney disease.糖尿病肾病中的固有免疫。
Nat Rev Nephrol. 2020 Apr;16(4):206-222. doi: 10.1038/s41581-019-0234-4. Epub 2020 Jan 15.
Zotero 插件